|
市場調査レポート
商品コード
1395618
細胞凍結保存の世界市場規模、シェア、産業動向分析レポート:コンポーネント別、最終用途別、地域別展望と予測、2023年~2030年Global Cell Cryopreservation Market Size, Share & Industry Trends Analysis Report By Component, By End-use, By Application (Stem Cells, Oocytes & Embryotic cells, Sperm Cells, Hepatocytes), By Regional Outlook and Forecast, 2023 - 2030 |
||||||
細胞凍結保存の世界市場規模、シェア、産業動向分析レポート:コンポーネント別、最終用途別、地域別展望と予測、2023年~2030年 |
出版日: 2023年11月30日
発行: KBV Research
ページ情報: 英文 420 Pages
納期: 即納可能
|
細胞凍結保存市場規模は2030年までに357億米ドルに達すると予測され、予測期間中のCAGRは20.3%の市場成長率で上昇する見込みです。
KBV Cardinalのマトリックスに掲載された分析によると、Thermo Fisher Scientific IncとDanaher Corporationが同市場の先駆者です。2023年8月、サーモフィッシャーサイエンティフィック社は、実験用冷蔵庫・冷凍庫のTSVシリーズを発売しました。発売された製品は、超低温フリーザーや凍結保存用貯蔵タンクを含む温度制御技術を提供し、温度の均一性と安定性を保証し、サンプルの劣化リスクを軽減します。Sartorius AG、Lonza Group AG、Merck KGAAなどの企業が、この市場における主要なイノベーターです。
COVID-19の影響分析
COVID-19パンデミックは市場に大きな影響を与えました。パンデミックは、患者サンプルの収集と保存を含むウイルスに関連する研究の急増につながっています。このため、凍結保存サービスや施設に対する需要が増加しました。COVID-19ワクチンの急速な開発には、広範な研究と試験が必要でした。その結果、ワクチン開発に使用される細胞株や材料の保存に対するニーズが高まっています。パンデミックは、将来の健康危機に対する備えの重要性を浮き彫りにしました。政府や組織は、将来の大流行に効果的に対応するため、設備の整ったバイオバンキングと凍結保存のインフラの必要性を認識し、これらの分野への投資を推進しました。このため、より高度で効率的な凍結保存技術や機器の開発が進んだ。
市場成長要因
卵子凍結サイクルの増加
卵子凍結への関心の高まりにより、不妊治療クリニック、体外受精センター、生殖医療専門医が提供する凍結保存サービスの需要が増加しています。これらの施設では、卵子凍結サービスを提供するために凍結保存機器や専門知識を含む必要なインフラが必要となります。卵子凍結の需要の高まりは、凍結保存技術や機器の技術的進歩に拍車をかけています。卵子凍結バンクは卵子凍結市場に不可欠な存在であり、凍結卵子の品質と生存率を維持するために、凍結保存に特化したソリューションと機器に依存しています。卵子凍結サイクルの拡大が市場の成長に寄与しています。
バイオバンクの増加と個別化医薬品の需要
世界のバイオバンクの設立と増加により、細胞凍結保存サービスに対する大きな需要が生まれています。これらのバイオバンクは、研究や臨床使用のために多様な生物学的サンプルを保存・保管する凍結保存技術に依存しています。個別化医療は、遺伝学や特定のニーズに基づいて個々の患者に合った医療を提供するもので、多くの場合、保存状態の良い生物学的サンプルへのアクセスが必要となります。凍結保存されたサンプルは、複数の疾患、薬剤反応、治療結果に関連する遺伝子マーカーやバイオマーカーを同定します。バイオバンクの増加と個別化医薬品の需要が市場を拡大しています。
市場抑制要因
細胞凍結保存の代替療法の利用可能性
代替法の費用対効果や利用しやすさは、その採用に影響を与える可能性があります。代替方法がより手頃な価格であったり、より専門的な機器を必要としない場合、特定の状況において普及する可能性があります。代替凍結保存法の採用は、その利点や適切な使用方法についての認識を高め、研究者や臨床医を教育することに依存するかもしれないです。凍結保存の代替法の有効性と安全性を検証することは複雑なプロセスです。代替方法は、マイクロ流体工学や3Dバイオプリンティングなど、他の技術やアプローチと統合される可能性があり、凍結保存市場の様相を変える可能性があります。これらの要因は、今後数年間の市場成長を低下させると思われます。
コンポーネントの展望
コンポーネントに基づき、市場は細胞凍結培地、機器、消耗品に区分されます。2022年には、消耗品部門が最大の売上シェアで市場を独占しました。細胞凍結保存の消耗品は、細胞や組織を超低温で保存・保管するために不可欠であり、一般的には液体窒素や超低温フリーザーで保管されます。これは主に、コンタミネーションが少ないなどの利点から、エンドユーザーによるクライオバイアル、クライオチューブ、その他の消耗品の採用が増加しているなどの要因によるものです。その他、慢性疾患の増加、生物製剤の需要拡大、エンドユーザーにおける凍結保存需要の高まりなどが、同分野の成長を後押しします。
消耗品の展望
消耗品タイプでは、市場はさらに極低温バイアル、極低温チューブ、クーラーボックス/コンテナ、その他に区分されます。2022年には、極低温バイアルセグメントが市場で最も高い収益シェアを占めました。極低温バイアルは、極端な寒さに強い材料で作られており、サンプルの完全性を確実に保持します。これは、研究者が特定のサンプルを効率的に見つけ、取り出すのに役立ちます。極低温バイアルは極端な温度に耐えるように設計されており、極低温環境でも安全に使用できます。超低温への暴露から研究者や研究室の人員を保護します。
細胞凍結培地の展望
細胞凍結培地タイプでは、市場はさらにエチレングリコール、ジメチルスルホキシド、グリセロール、その他に分けられます。2022年には、エチレングリコールセグメントが市場で最も高い収益シェアを記録しました。エチレングリコールは、細胞内に入り込んで氷結晶の形成を抑えることで、凍結保護剤として作用します。これは細胞の生存にとって重要です。凍結培地中のエチレングリコールの濃度は、特定のプロトコールや保存する細胞の種類によって変えることができます。濃度は、潜在的な毒性を最小限に抑えながら、効果的な凍結保護を提供するために慎重に選択されます。
装置の展望
装置タイプでは、市場はさらにフリーザー、インキュベーター、液体窒素供給タンクに分類されます。2022年には、フリーザセグメントが市場で最大の収益シェアを獲得しました。フリーザーは、細胞、組織、その他の生物学的材料を含む生物学的サンプルを超低温で保存するために必要な保存条件を提供することで、市場で重要な役割を果たしています。フリーザーは、科学や医療の進歩のために貴重な生物試料の長期保存を保証する、市場にとって不可欠なツールです。
最終用途の展望
市場は最終用途別に、バイオ医薬品・製薬会社、研究機関、バイオバンク、体外受精クリニック、その他に分類されます。2022年の市場では、バイオバンク分野が大きな収益シェアを獲得しました。バイオバンクは、研究や臨床応用のための組織や細胞を含む生物学的サンプルの保管・保存に不可欠です。国立医学図書館によると、経済先進国では2022年に人口100万人当たり少なくとも11のバイオバンクが存在します。その目標は、国際的なバイオバンクの接続を簡素化し、より大規模で強固な遺伝子データ調査を可能にすることです。このプログラムは、より多くの遺伝的祖先の多様性を追加することにより、新規の疾患関連遺伝的変異を検出する可能性を高めることを意図しています。
用途の展望
用途に基づき、市場は幹細胞、卵母細胞・胚細胞、精子細胞、肝細胞、その他に細分化されます。2022年には、幹細胞分野が市場で最大の収益シェアを占めています。幹細胞の応用は、細胞の凍結保存に大きく依存しており、これにより幹細胞は細胞や遺伝子に変化を与えることなく保存、保管、輸送されます。世界保健連合(WHF)の2023年の記録によると、世界で5億人以上が心血管障害(CVD)に罹患しており、2021年には約2,050万人が死亡し、世界全体の死亡者数の3分の1近くを占めています。高齢者人口の増加は、座りがちなライフスタイルと相まって、心血管疾患の負担を増大させ、同分野の成長拡大に拍車をかけると思われます。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。アジア太平洋地域は、2022年の市場で顕著な収益シェアを記録しました。アジア太平洋地域、特に中国と日本で細胞凍結保存技術の採用が増加しているためです。同地域は人口が多く、慢性疾患の蔓延、高齢者の増加、不妊症の割合が急増しているため、同地域の市場拡大の余地は十分にあります。
The Global Cell Cryopreservation Market size is expected to reach $35.7 billion by 2030, rising at a market growth of 20.3% CAGR during the forecast period.
The surge in stem cell research has led to a growing demand for the banking of various types of stem cells, including embryonic stem cells, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells. Therefore, Stem Cells segment generated $3,228.6 million revenue in the market in 2022. As a result, the increasing focus on stem cell research has driven innovations in cryopreservation techniques specifically tailored to the needs of different stem cell types. These advancements have improved the viability and functionality of cryopreserved stem cells, expanding the capabilities of the market.
The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, In June, 2023, BioLife Solutions, Inc. unveiled IntelliRate i67C, a new, large-capacity controlled-rate freezer. This launch aimed to fulfill a crucial customer requirement for higher volume production of cell therapies. Moreover, In January, 2021, Lonza Group AG released cryopreserved Leukopaks, an expansion in renowned human primary cell offerings. The launched product would allow long-distance transportation of leukapheresis products without the concern of decreased cell viability encountered with fresh Leukopaks.
Based on the Analysis presented in the KBV Cardinal matrix; Thermo Fisher Scientific Inc and Danaher Corporation are the forerunners in the Market. In August, 2023, Thermo Fisher Scientific Inc. launched the TSV series of laboratory refrigerators and freezers, the Made in India. The launched product would offer controlled temperature technologies including ultra-low temperature freezers and cryopreservation storage tanks that guarantee temperature uniformity and stability, mitigating the risk of sample degradation. Companies such as Sartorius AG, Lonza Group AG and Merck KGAA are some of the key innovators in the Market.
COVID-19 Impact Analysis
The COVID-19 pandemic had a substantial impact on the market. The pandemic led to a surge in research related to the virus, including the collection and storage of patient samples. This increased demand for cryopreservation services and facilities. The rapid development of COVID-19 vaccines required extensive research and testing. This, in turn, led to an increased need for the preservation of cell lines and materials used in vaccine development. The pandemic highlighted the importance of preparedness for future health crises. Governments and organizations recognized the need for well-equipped biobanking and cryopreservation infrastructure to respond effectively to future outbreaks, which drove investment in these areas. This led to the development of more advanced and efficient cryopreservation techniques and equipment.
Market Growth Factors
Increasing number of egg-freezing cycles
The rising interest in egg freezing has increased the demand for cryopreservation services provided by fertility clinics, IVF centers, and reproductive medicine specialists. These facilities require the necessary infrastructure, including cryopreservation equipment and expertise, to offer egg-freezing services. The growing demand for egg freezing has spurred technological advancements in cryopreservation techniques and equipment. These banks are an integral part of the market, and they rely on specialized cryopreservation solutions and equipment to maintain the quality and viability of frozen eggs. The expansion of egg-freezing cycles has contributed to the growth of the market.
Growing number of biobanks and demand for personalized medicines
The establishment and growth of biobanks worldwide have created a significant demand for cell cryopreservation services. These biobanks rely on cryopreservation techniques to store and preserve diverse biological samples for research and clinical use. Personalized medicine, which tailors medical treatments to individual patients based on their genetics and specific needs, often requires access to well-preserved biological samples. Cryopreserved samples identify genetic markers and biomarkers associated with multiple diseases, drug responses, and treatment outcomes. The increasing number of biobanks and the demand for personalized medicines have expanded the market.
Market Restraining Factors
Availability of alternative therapies for cell cryopreservation
The cost-effectiveness and accessibility of alternative methods can influence their adoption. If alternative methods are more affordable or require less specialized equipment, they may gain popularity in specific contexts. Adopting alternative cryopreservation methods may depend on raising awareness and educating researchers and clinicians about their benefits and proper usage. Validating the effectiveness and safety of alternative methods for cryopreservation can be a complex process. Alternative methods may be integrated with other technologies or approaches, such as microfluidics or 3D bioprinting, which could change the landscape of the cryopreservation market. These factors will decline the market growth in the coming years.
Component Outlook
On the basis of component, the market is segmented into cell freezing media, equipment, and consumables. In 2022, the consumables segment dominated the market with the maximum revenue share. Cell cryopreservation consumable products are essential in preserving and storing cells and tissues at very low temperatures, typically in liquid nitrogen or ultra-low temperature freezers. This is primarily due to factors such as the increasing adoption of cryovials, cryotubes, and other consumables by end-users due to benefits such as lower contamination. Other aspects, including the rising majority of chronic diseases, growing demand for biologics, and rising demand for cryopreservation among end-users, will propel the segment's growth.
Consumables Outlook
Under consumables type, the market is further segmented into cryogenic vials, cryogenic tubes, cooler boxes/containers, and others. In 2022, the cryogenic vials segment held the highest revenue share in the market. Cryogenic vials are made of materials that are highly resistant to extreme cold, ensuring the preservation of sample integrity. This helps researchers efficiently locate and retrieve specific samples. Cryogenic vials are designed to withstand extreme temperatures and are safe for use in cryogenic environments. They protect researchers and laboratory personnel from exposure to ultra-low temperatures.
Cell Freezing Media Outlook
Under cell freezing media type, the market is further divided into ethylene glycol, dimethyl sulfoxide, glycerol, and others. In 2022, the ethylene glycol segment registered the highest revenue share in the market. Ethylene glycol acts as a cryoprotective agent by entering the cells and reducing ice crystal formation. This is important for cell survival. The concentration of ethylene glycol in freezing media can change depending on the specific protocol and the preserved cell type. The concentration is carefully chosen to provide effective cryoprotection while minimizing potential toxicity.
Equipment Outlook
Under equipment type, the market is further classified into freezers, incubators, and liquid nitrogen supply tanks. In 2022, the freezers segment generated the largest revenue share in the market. Freezers play a critical role in the market by providing the necessary storage conditions for preserving biological samples, including cells, tissues, and other biological materials, at ultra-low temperatures. They are vital tools in the market, ensuring the long-term preservation of valuable biological materials for scientific and medical advancements.
End-use Outlook
By end-use, the market is categorised into biopharmaceutical & pharmaceutical companies, research institutes, biobanks, IVF clinics, and others. The biobanks segment garnered a significant revenue share in the market in 2022. Biobanks are critical in the storage and preservation of biological samples, including tissues and cells, for research and clinical applications. According to the National Library of Medicine, economically developed countries had at least 11 biobanks per million people in 2022. Its goal is to simplify the connection of international biobanks, enabling larger and more robust genetic data investigations. This program intends to increase the possibility of detecting novel disease-associated genetic variations by adding more genetic ancestral variety.
Application Outlook
Based on application, the market is fragmented into stem cells, oocytes & embryotic cells, sperm cells, hepatocytes, and others. In 2022, the stem cells segment witnessed the largest revenue share in the market. Stem cell applications rely heavily on cell cryopreservation, which allows stem cells to be preserved, stored, and transported without cellular or genetic change. As per the World Health Federation- 2023 records, over half a billion people worldwide are affected by cardiovascular disorders (CVDs), with around 20.5 million deaths occurring in 2021, accounting for nearly one-third of all deaths globally. The growing senior population, combined with sedentary lifestyles, will raise the burden of cardiovascular disease, fueling the expansion of the segment growth.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific region recorded a remarkable revenue share in the market in 2022. Due to the rising adoption of cell cryopreservation technologies in the Asia Pacific region, especially throughout China and Japan. Because of the region's large population, the prevalence of chronic diseases, the rising number of older people, and the surge in the rate of infertility, there is enough scope for expanding the market in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., Sartorius AG, PromoCell GmbH, Lonza Group Ltd., HiMedia Laboratories Pvt. Ltd., Corning Incorporated, BioLife Solutions, Inc., Eppendorf SE and Danaher Corporation.
Recent Strategies Deployed in Cell Cryopreservation Market
Mergers & Acquisition
Jul-2023: Sartorius AG acquired Polyplus, a leading provider of innovative technologies for cell and gene therapies. Through this acquisition, both companies aimed to widen their focus in adjacent technologies like plasmid design, and protein and plasmid manufacturing, broadening their suites for gene therapies as well as gene-modified cell therapies.
Jul-2021: Sartorius AG took over Xell AG, an innovative partner for the biotech and pharmaceutical industry. This acquisition aimed to widen Sartorius's current media portfolio specifically by specialized media for manufacturing viral vectors and in the area of media analytics.
Mar-2020: Eppendorf AG took over Koki Holdings Co., Ltd., a Japan-based power/air tool manufacturer. This acquisition aimed to widen the Eppendorf centrifuge business and solidify its strong market position as one of the world's leading makers of high-end centrifuges for the pharma and life science industries including academic and commercial research.
Nov-2019: BioLife Solutions, Inc. acquired Custom Biogenic Systems, Inc., a privately held company with operations located near Detroit. This acquisition aimed to deepen engagement with BioLife Solutions cell and gene therapy customers and increase touchpoints in their manufacturing, storage, and distribution workflows.
Product Launches and Product Expansions
Aug-2023: Thermo Fisher Scientific Inc. launched the TSV series of laboratory refrigerators and freezers, the Made in India. The launched product would offer controlled temperature technologies including ultra-low temperature freezers and cryopreservation storage tanks that guarantee temperature uniformity and stability, mitigating the risk of sample degradation.
Jun-2023: BioLife Solutions, Inc. unveiled IntelliRate i67C, a new, large-capacity controlled-rate freezer. This launch aimed to fulfill a crucial customer requirement for higher volume production of cell therapies.
Oct-2022: Thermo Fisher Scientific Inc. introduced the new Gibco CTS DynaCellect Magnetic Separation System, to improve the cell therapy manufacturing process. The launched product would enable customers to commercialize therapies faster and potentially save more lives.
Apr-2021: BioLife Solutions, Inc. introduced a new suite of high-capacity controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company. The launched product would be a critical component in the customer's cold chain management of several allogeneic cell therapies in development.
Jan-2021: Lonza Group AG released cryopreserved Leukopaks, an expansion in renowned human primary cell offerings. The launched product would allow long-distance transportation of leukapheresis products without the concern of decreased cell viability encountered with fresh Leukopaks.
May-2020: Sartorius AG unveiled the Incucyte SX5 Live-Cell Analysis System, the latest in the company's portfolio of live-cell analysis products. The launched product would provide new capabilities, including novel optics, a new line of paired reagents, and purpose-built software to allow researchers to draw greater insight from each live cell experiment.
Partnerships, Collaborations & Agreements
Jul-2023: Sartorius AG came into collaboration with Qkine, a manufacturer of animal-free, highly bioactive, and innovative proteins. This collaboration aimed to allow rapid advancement in the science of advanced cell models.
Jun-2023: Sartorius AG collaborated with Stanford University, the leading research and teaching institution. This collaboration aimed to develop a Scalable Platform for Large-Scale Human iPSC Production.
Dec-2021: Sartorius AG partnered with HOF Sonderanlagenbau, a machinery company that manufactures freeze-drying, loading and unloading systems, freezing and thawing devices. This partnership aimed to empower Sartorius AG's leading position in the freeze-thaw market.
Dec-2021: Lonza Group AG collaborated with Agilent Technologies, a leader in life sciences analytics, diagnostics, and applied chemical markets. This collaboration aimed to change the way personalized cell therapies are manufactured and realized.
Jan-2021: Sartorius AG collaborated with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks. This collaboration aimed to scale of hMSC manufacturing for regenerative medicine by leveraging the best-in-class solutions of both companies to significantly decrease process development efforts.
Expansion
Jul-2023: Sartorius AG opened a cell culture media manufacturing facility in Yauco, Puerto Rico. The new facility would widen the company's cell culture media capacities, with a focus on customers in the Americas region.
Market Segments covered in the Report:
By Component
By End-use
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research